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Abstract—Glutamate receptors have been proposed to medi-
ate the apoptotic actions of glucocorticoids in hippocampal
cells. To further analyze the role of glutamate receptors in
this process, we pretreated primary hippocampal cells from
neonatal (postnatal day 4) rats with antagonists of ionotropic
glutamate receptor (iGluR) and metabotropic glutamate re-
ceptor (mGluR) antagonists before exposure to the specific
glucocorticoid receptor agonist dexamethasone (DEX) at a
dose of 1 M. Dizocilpine (MK801; a general N-methyl-D-
aspartic acid [NMDA] receptor antagonist, NMDAR antago-
nist) and ifenprodil (a specific ligand of the NMDAR 2B sub-
unit, NR2B), were used to block iGluR; (RS)--ethyl-4-car-
boxyphenylglycine (E4CPG) and (RS)--cyclopropyl-4-
phosphonophenyl-glycine (CPPG) were employed as I/II
(E4CPG) and II/III (CPPG) mGluR antagonists. Blockade of
iGluR resulted in a significant attenuation of DEX-induced
cell death; the finding that ifenprodil exerted a similar po-
tency to MK801 demonstrates the involvement of NR2B re-
ceptors in glucocorticoid-induced cell death. Apoptosis ac-
counted for a significant amount of the cell loss observed, as
detected by terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling histochemistry for the in situ labeling
of DNA breaks; apoptotic cells were distinguished from ne-
crosis on the basis of morphological criteria, including chro-
matin condensation, membrane blebbing and presence of
apoptotic bodies. Treatment with E4CPG and CPPG com-
pletely abolished the apoptotic response to DEX, thus show-
ing the additional contribution of mGluR to the phenomenon.
Further, dose-response studies with NMDA revealed that
whereas high (10 M) doses of NMDA themselves elicit cy-
totoxic responses, low (1–5 M) concentrations of NMDA can
effectively oppose DEX-induced cell death. Interestingly, the
neuroprotective actions of low dose NMDA stimulation were
abolished when either synaptic or extrasynaptic NMDA re-
ceptors were blocked with MK801 in combination with the
GABA receptor antagonist bicuculline (synaptic) or ifenprodil
(extrasynaptic). In summary, the present data show that both
iGluR and mGluR mediate the neurotoxic effects of glucocor-
ticoids on hippocampal cells and that pre-treatment with low
doses of NMDA, by acting on synaptic and extrasynaptic
receptors, render hippocampal cells less vulnerable to glu-
cocorticoid insults. © 2003 IBRO. Published by Elsevier Ltd.
All rights reserved.
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Glucocorticoids (represented endogenously by cortisol
and corticosterone) are hormones secreted by the adrenal
cortex in response to stress. Acting through hippocampal
receptors (glucocorticoid receptors [GR]), they play an
important role in the physiological and behavioral adaptive
responses to stress (Sapolsky et al., 2000). On the other
hand, there is an abundant literature indicating that exces-
sive glucocorticoid secretion can result in damaging effects
on adaptive mechanisms as well as on the viability of
structural integrity of neurons in the hippocampus. Notably,
activation of GR leads to neuritic atrophy and death of
neurons, a phenomenon that has been linked to disorders
of mood and cognition as well as neuroendocrine dysregu-
lation (De Kloet et al., 1998; McEwen, 2000; Sapolsky,
2000; Abraham et al., 2001; Sousa and Almeida, 2002).
Despite some conflicting reports (Masters et al., 1989; Roy
and Sapolsky, 2003), work from our laboratory has dem-
onstrated that apoptosis is at least one of the forms of cell
death resulting from exposure to glucocorticoids; that con-
clusion was made in light of the presence of specific mor-
phological features (see Hassan et al., 1996) and the
activation of key pro-apoptotic versus anti-apoptotic genes
(Almeida et al., 2000). Several different, although not mu-
tually exclusive, mechanisms have been implicated in
these GR-mediated neurodegenerative effects; these in-
clude reduced glucose uptake by neurons, increases in the
extracellular concentrations of glutamate with concomitant
elevations in intracellular Ca2 levels (Sapolsky, 2000).
Glutamate is the dominant neurotransmitter in the
brain, being found in most excitatory synapses. Its actions
are mediated by ionotropic glutamate receptors (iGluR)
which are directly associated with ligand-gated ionophores
permitting Ca2 influx, and metabotropic glutamate recep-
tors (mGluR); the latter are G protein-coupled receptors
which can activate secondary messengers such as cAMP
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or diacylglycerol and phosphoinositides (Lipton and
Rosenberg, 1994; Pin and Duvoisin, 1995). Both types of
receptor can activate downstream pathways that deter-
mine cell survival or death. Their dichotomous actions
appear to result from differences in the duration and mag-
nitude of action and the subsequent levels of intracellular
Ca2. Synaptic N-methyl-D-aspartic acid (NMDA) receptor
(NMDAR), which respond to physiological (low dose)
NMDAR activation, have been associated with the promo-
tion of cell survival; in contrast, extrasynaptic NMDAR
located on the cell body, axon and dendritic spines (Li et
al., 1998; Tovar and Westbrook, 1999) have been associ-
ated with apoptosis (Hardingham et al., 2002; Riccio and
Ginty, 2002). As compared with the synaptic NMDAR, the
extrasynaptic NMDAR is characterized by a faster and
more extensive rundown of peak current (Li et al., 2002). It
is currently believed that while activation of extrasynaptic
NMDAR is a rare event under normal conditions, it be-
comes more common during acute cellular insults or
pathological situations when glutamate transporters oper-
ate in reverse, thereby increasing extracellular concentra-
tions of glutamate (Rossi et al., 2000).
Gluocorticoids and glutamate receptor (GluR) share an
intimate relationship: (i) glucocorticoids can increase hip-
pocampal cell vulnerability to GluR activation (Armanini et
al., 1990); (ii) GR activation leads to an up-regulation of the
expression of one type of GluR, the ionotropic NMDAR,
strongly implicated in neurotoxicity (Weiland et al., 1997);
(iii) elevated glucocorticoid levels have been associated
with an increase in glutamatergic transmission
(Moghaddam et al., 1994) and (iv) glutamate can enhance
GR activation (Gursoy et al., 2001). In light of these inter-
actions, and given the neurotoxic potential of each, gluta-
mate and glucocorticoids, the many possibilities for mutual
potentiation of each other’s effects can be easily appreci-
ated.
Blockade of the NMDAR was previously shown to me-
diate the inhibitory effects of stress (during which glucocor-
ticoid secretion is increased) on neurogenesis in the hip-
pocampus; this observation provides a clue as to the par-
ticular subtype of GluR that may mediate at least some
glucocorticoid actions (Gould et al., 1997). The studies
described here were designed to provide further insight
into the role of GluR in dexamethasone (DEX)-induced cell
death in the hippocampus. To do so, we resorted to an in
vitro model, treating primary hippocampal cells from post-
natal day 4 (P4) rats with ionotropic and metabotropic
GluR antagonists, to evaluate the role of each of these
receptors in DEX-induced apoptosis. A further objective of
this study was to explore the possibility of an additive effect
of DEX and NMDA; for this, hippocampal cells were ex-
posed to a range of NMDA concentrations before subse-
quent treatment with DEX. Finally, the role of extrasynaptic
versus synaptic NMDAR in these events was examined
with the aid of ifenprodil, a selective antagonist of extra-
synaptic NMDA-R, and a combination of MK-801 and bicu-
culline to block synaptic NMDAR.
EXPERIMENTAL PROCEDURES
Primary cell culture
Cultures were prepared from Wistar rats aged 4 days (P4; Charles
River, Sulzfeld, Germany), following a protocol previously devel-
oped in our laboratory (Crochemore, 2000). Briefly, hippocampal
slices were digested using the Papain Dissociation System from
Worthington Biochemicals (Lakewood, NJ, USA) and the dissoci-
ated cells plated on poly-d-lysine-coated glass coverslips at a
density of 400 cells/mm2. Cultures were maintained in Neurobasal
A medium to which 2% B27 supplement, 1 mM GlutamaxI (Invitro-
gen, Eggenstein, Germany) and 0.1mg/ml kanamycin were added
(all supplements from Invitrogen). Culture medium was half-re-
newed every 3 days. Experiments were started 6 days after plat-
ing. Immunocytochemical analysis of the cultures revealed that
the cultures comprised ca. 90% neurons (neuronal markers used:
NeuN, TuJ1 and doublecortin) and ca. 10% astro-glial cells (glial
fibrillary acidic protein-positive).
Drugs
DEX, obtained as a freely-soluble sodium salt from Merck (Darm-
stadt, Germany), was used at a concentration of 1 M in all
experiments; DEX treatment was always added to cultures after
3–6 days in vitro for 72 h. In all experiments, the mineralocorticoid
receptor (MR) antagonist spironolactone was added (10 M) in
order to antagonize interfering effects from low (nanomolar range)
MR-activating doses of corticosterone present in the culture me-
dium (Crochemore, 2000). NMDA was obtained from Sigma
Chemicals (Deisenhofen, Germany). All other drugs were pur-
chased from Tocris (Bristol, UK). They included bicuculline (used
at 50 M), MK801 (a general NMDAR antagonist; used at 10 M),
ifenprodil (a specific ligand of the NMDAR 2B subunit; used at
10 M), and (RS)--ethyl-4-carboxyphenylglycine (E4CPG) and
(RS)--cyclopropyl-4-phosphonophenyl-glycine (CPPG), antago-
nists of mGluR I/II and mGluRII/III, respectively (both used at
10 M). The precise treatment protocols used in individual exper-
iments are detailed below.
Experiment 1: attenuation of DEX-induced apoptosis
by GluR blockade
Hippocampal cells were pretreated with either MK801, ifenprodil
or a combination of CPPG and E4CPG for 15 min before addition
of DEX (continued presence of antagonists) for 72 h after which
cultures were analyzed for the incidence of apoptosis.
Experiment 2: dose-dependent effects of NMDA on
DEX-induced cell death
In the first part of this experiment, cells were treated with NMDA
for 15 min at doses between 1 and 10 M; assessment of cell
death (apoptosis and necrosis) was performed 72 h later. In order
to maximize the NMDA effects, the usual culture medium (sup-
plemented Neurobasal A) was replaced by and added to the cells
in Mg2 free Earle’s buffered salt solution (EBSS; Invitrogen)
containing 10 M glycine. The treatment schedule for the second
part of the experiment was as follows: pre-exposure to NMDA
(1–10 M in Mg2 free EBSS plus 10 M glycine) for 15 min,
followed by a washout step, and addition of DEX (1 M in sup-
plemented Neurobasal A) for 72 h. At this point, the cultures were
fixed and processed for the detection of apoptosis.
Experiment 3: role of synaptic receptors in NMDA-
associated neuroprotection
After pre-exposure to a mixture of bicuculline and MK801 (50 M
and 10 M, both in Mg2 free EBSS plus 10 M glycine) for 15
min, a washout step, NMDA (1 or 5 M) was added and incubation
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continued for a further 15 min. A thorough washout step was then
performed and cells were subsequently treated with DEX (1 M in
supplemented Neurobasal A) and maintained for 72 h when they
were processed for the detection of apoptosis.
Experiment 4: attenuation of NMDA-induced
neuroprotection by ifenprodil
After pre-exposure to ifenprodil (10 M) and NMDA (1 or 5 M in
Mg2 free EBSS plus 10 M glycine) for 15 min, and a washout
step, cultures were then transferred to supplemented Neurobasal
A medium containing DEX at a concentration of 1 M for 72 h
before being examined for apoptosis.
Cell death assay
Cell death was examined in 4% paraformaldehyde-fixed cells by
terminal deoxynucleotidyl transferase-mediated dUTP nick-end
labeling (TUNEL) histochemistry or Hoechst 33342 staining.
When TUNEL histochemistry was to be performed, permeabiliza-
tion (0.1% Triton X-100) and peroxidase blocking (1% H2O2) steps
were carried out before application of the TUNEL assay as previ-
ously described (Almeida et al., 2000). Apoptotic cells were char-
acterized by dark brown nuclear staining; only those nuclei show-
ing evidence of DNA fragmentation without plasma membrane
damage were taken to be apoptotic cells. Hoechst staining was
used in a few cases to confirm TUNEL staining. Fixed cells were
incubated with the dye (1:1000) for 15 min before examination
under a fluorescence microscope. Apoptotic versus total cells (%)
were quantified in at least five randomly chosen microscopic fields
(0.072 mm2, magnification of 400) across the long axis of the
coverslips on which cells were grown; an average of 1000 cells
were sampled on each coverslip and the results shown represent
values from six to 10 coverslips per treatment.
Statistical analysis
All data are depicted as meansS.D. and represent the observa-
tions from three to five independent experiments, with three to four
replicates for each data point. Data were analyzed for statistical
significance using ANOVA and appropriate post hoc tests (Stu-
dent-Newman-Keuls or Kruskal-Wallis multiple comparison proce-
dures) in which P0.05 was set as the minimum level of
significance.
RESULTS
Throughout, TUNEL-positive cells were considered to be
apoptotic only if they showed the characteristic morpho-
logical features of apoptosis (see Hassan et al., 1996).
Under control conditions (no drug treatment), basal rates
of apoptosis were 10.91.9% (TUNEL-positive cells meet-
ing morphological criteria of apoptosis expressed as a
percentage of total number of cells; meanS.E.M.). Rep-
resentative microscopic fields from TUNEL-stained control
and DEX-treated cultures are shown in Fig. 1.
Attenuation of DEX-induced apoptosis by GluR
blockade (Fig. 2)
Apoptosis was significantly increased in hippocampal cul-
tures exposed for 72 h to the GR-specific agonist DEX at a
dose of 106M (P0.05); the apoptotic effects of DEX
were abrogated by the GR antagonist RU 38486 (mifepris-
tone, 105M), indicating mediation by GR (data not
shown). Subsequent experiments involved pretreatment of
cells with various GluR antagonists (at 105M for 30 min
before the introduction of, and during exposure to, DEX at
106M). Concomitant treatment with the general NMDAR
antagonist MK801 or the NR2B-specific antagonist ifen-
prodil rescued cells from DEX-induced apoptosis (P0.01)
to levels that were not significantly different from those
observed under drug-naive conditions. In the absence of
DEX, MK801 and ifenprodil did not exert significant effects
on the rate of apoptosis in the cultures (data not shown).
Application of the mGluR antagonists E4CPG (mGluR I/II)
and CPPG (mGluR II/III), while not exerting any effects on
their own (data not shown), abolished the apoptotic actions
of DEX (P0.001) and significantly improved basal cell
survival (P0.05), i.e. the protective effects afforded by the
mGluR antagonists exceeded those provided by NMDAR
blockade (P0.01 or P0.001).
The results of this experiment therefore conclusively
demonstrate that induction of apoptosis by DEX is medi-
ated by GR and, in turn, by iGluR and mGluR.
Dose-dependent effects of NMDA on DEX-induced
cell death (Fig. 3)
In view of the above findings implicating NMDAR involve-
ment in the apoptotic actions of DEX, we first conducted a
dose-response study with NMDA. The NMDA was added
for 15 min in Mg2-free medium containing 10 M glycine.
As shown in Fig. 3A, the two lower doses of NMDA (1 and
5 M) did not influence hippocampal survival, as assessed
72 h after application of the drug. In contrast, the highest
dose tested (10 M) led to a significant increase in cell
death (P0.05). Based on this result as well as reports that
GR activation can increase the vulnerability of hippocam-
pal cells to glutamatergic toxicity (Armanini et al., 1990),
we subsequently examined whether pre-exposure to
NMDA can influence the magnitude of DEX-induced cell
death; in these experiments, cells were pre-treated with
NMDA and then exposed to DEX (in the absence of
NMDA) for 72 h. As shown in Fig. 3B, the highest dose of
NMDA (10 M) resulted in cell death but did not potentiate
the effects of DEX. On the other hand, and contrary to our
predictions, NMDA at one and 5 M was found to signifi-
cantly attenuate the apoptotic actions of DEX (P0.001
and P0.01).
These results demonstrate that low doses of NMDA
can counteract the cell death-inducing effects of DEX.
Synaptic receptors mediate the neuroprotective
effects of NMDA (Fig. 4)
Recent evidence suggests that extrasynaptic NMDAR
may be responsible for triggering excitotoxicity; in con-
trast, synaptic NMDAR are thought to activate cell sur-
vival-promoting signaling cascades (Hardingham et al.,
2002). In contrast to NMDA receptor subunit 2A (NR2A)
subunits which are mainly found in synaptic NMDAR,
NMDA receptor subunit 2B (NR2B) predominate in ex-
trasynaptic NMDAR (Tovar and Westbrook, 1999). Be-
cause of this, and the fact that we observed that DEX-
induced apoptosis could be attenuated by antagonism of
the NR2B subunit with ifenprodil (Fig. 2), it was of inter-
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est to examine the role of extrasynaptic NMDAR in our
paradigm. Following a recently described experimental
paradigm (Hardingham et al., 2002), we applied the
GABA receptor antagonist bicuculline (1 M) together
with MK801 (5 M) in order to subsequently be able to
activate extrasynaptic NMDAR selectively. This treat-
ment paradigm abolished the ability of the low doses of
NMDA (1 and 5 M) to counteract the apoptosis-induc-
ing effects of DEX (P0.001 and P0.05).
These findings conform with the view that synaptic
NMDAR play a permissive role in the neuroprotective ac-
tions of low doses of NMDA.
Fig. 1. DEX increases apoptosis in primary hippocampal cell cultures. Photomicrographs show TUNEL-staining in control (upper panel) and
DEX-treated (lower panel) cells. Examples of TUNEL-positive cells displaying some of the morphological features used to designate apoptotic cells
in this study (e.g. shrunken cell body or apoptotic bodies) are marked with black arrows. Note that the relative number of apoptotic versus healthy cells
(white arrows) is increased after exposure to DEX (lower panel).
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Ifenprodil attenuates low dose NMDA-induced
neuroprotection (Fig. 5)
NR2B are predominantly expressed at extrasynaptic sites
which have been associated with neurotoxicity (Harding-
ham et al., 2002). As mentioned, ifenprodil is a selective
inhibitor of the NR2B subunit of the NMDAR (Gotti et al.,
1988) and has proven neuroprotective efficacy in animal
models of degeneration (Kemp and McKernan, 2002). The
results depicted in Fig. 2 show that ifenprodil can reduce
the cytotoxic effects of DEX. Since the results of the pre-
vious experiment (Fig. 4) indicated that synaptic receptors
mediate the protective effects of low doses of NMDA, the
question arose as to the impact of NR2B extrasynaptic
receptor antagonism on DEX-induced cell death. Because
ifenprodil is an activity-dependent NR2B antagonist, cells
were pre-treated with NMDA (1 and 5 M) and ifenprodil
(10 M) for 15 min, before wash-out and exposure to DEX
(1 M) for 72 h. Contrary to our prediction, hippocampal
cultures treated according to this paradigm displayed more
apoptosis than those exposed only to the NMDA pulse
followed by DEX (P0.01 and P0.05). Thus, these ob-
servations indicate that transient blockade of NR2B can
prevent low doses of NMDA from exerting protective ac-
tions against DEX-induced apoptosis.
DISCUSSION
Glucocorticoids fulfill several important functions in the hip-
pocampus, including cognition, mood and neuroendocrine
regulation. Nevertheless, high levels of both endogenous and
therapeutic glucocorticoids can affect hippocampal function
deleteriously. These undesired effects have been proposed
to result from either neuronal atrophy and, in extreme cases,
neuronal cell death of certain principal cells of the hippocam-
pus (for review, see Sousa and Almeida, 2002).
Glucocorticoids can exert rapid, transient effects on
neuronal excitability involving increased cytosolic concen-
trations of Ca2 (Nair et al., 1998). However, glucocorti-
coid actions are best known to be mediated through GR
which are transcription factors and our group has previ-
Fig. 2. Attenuation of DEX-induced apoptosis by GluR blockade.
Treatment of hippocampal cultures with MK801 (NMDAR antagonist),
ifenprodil (IFEN; selective NR2B subunit antagonist) and E4CPPG/
CPPG (antagonists of mGluRI/II and mGluRII/III, respectively) for 15
min before and during application of DEX (1 M) resulted in a signif-
icant reduction in DEX-induced apoptosis, as measured by TUNEL
histochemistry. All of the antagonists were used at 10 M. ** and ***
indicate P0.01 and0.001, respectively. Results represent
meansS.D. from five experiments, with three replicates for each data
point. Fig. 3. Dose-dependent effects of NMDA on DEX-induced cell death.
Cell death was assessed after treatment of cultures for 15 min with
NMDA ranging from 1 to 10 M. A. Dose-response curve showing that
1 and 5 M NMDA did not have affect on cell survival, whereas 10 M
of the drug significantly stimulated cell death. Note that data shown
refer only to counts of TUNEL-positive cells, although after exposure to
10 M NMDA, there was an increase in the number of cells showing
signs of necrosis. B. Demonstration that pretreatment with low, sub-
toxic doses of NMDA (1 and 5 M) can attenuate DEX-induced apo-
ptosis. The stippled area represents the effects of treatment with 1 M
of DEX for 72 h. All values shown are meansS.D., derived from five
experiments (in which each data point was replicated four times). *, **
and *** indicate significant differences where P0.05,  0.01 and
0.001, respectively.
J. Lu et al. / Neuroscience 121 (2003) 123–131 127
ously elucidated some of the cell death-related molecular
pathways triggered by exposure to the potent GR agonist
DEX (Almeida et al., 2000). Thus, glucocorticoid effects on
hippocampal structure and function do not necessarily re-
sult from one exclusive mechanism (electrophysiological
versus genomic) but rather may occur as a result of inte-
grated signals arising from both the cell membrane and
transcriptional activity. For example, by repressing the
transcription of Ca2 channel and Ca2 extrusion pump
genes (Bhargava et al., 2000), glucocorticoids contribute
to long-term alterations in the dynamics of intracellular
Ca2 levels, including those originating at the plasma
membrane (Kerr et al., 1992; Elliott and Sapolsky, 1993;
Nair et al., 1998; Bhargava et al., 2000).
Exaggerated and chronic elevations in intracellular
Ca2 accompany glutamatergic excitotoxicity (Choi, 1991;
Coyle and Puttfarcken, 1993) and have also been pro-
posed to at least partially underlie the neurotoxic effects of
glucocorticoids (Joe¨ls, 2001). Increases in cytosolic Ca2
concentrations result from the activation of both iGluR and
mGluR, albeit through different mechanisms: iGluR stimu-
late the influx of Ca2 from the extracellular space,
whereas mGluR mobilize Ca2 from intracellular reser-
voirs (Maiese et al., 1999; Otani et al., 2002). Glucocorti-
coids are known to increase NMDAR expression and glu-
tamate synthesis and extracellular accumulation (Weiland
et al., 1997; Moghaddam et al., 1994), and to potentiate
glutamate-induced cell death (Goodman et al., 1996; Behl
et al., 1997; Abraham et al., 2001; Johnson et al., 2002).
To date, however, earlier suggestions that glutamatergic
mechanisms may play an intermediary role in glucocorti-
coid-induced cell death have remained largely unsup-
ported by firm experimental evidence. The data presented
in this paper fill that gap by demonstrating that iGluR (here,
only the NMDAR type was studied) and mGluR mediate at
least some of the apoptotic effects of DEX in primary
hippocampal cultures. With respect to the involvement of
iGluR, our data show that general blockade of NMDAR
with MK801 significantly attenuates DEX-triggered cell
death (Fig. 2).
GluR are well-recognized triggers of neuronal cell
death and may occur either acutely upon activation or after
a period of delay (Choi, 1991). These two forms of neuro-
nal death are distinguishable on the basis of their morpho-
logical characteristics and ionic dependence. The rapid-
onset form is necrotic in nature, characterized by cell swell-
ing, intact nuclei with diffuse nucleoplasm, disrupted cell
membrane and ultimate cell lysis. In contrast, the delayed
Fig. 4. Synaptic receptors mediate the neuroprotective effects of
NMDA. Synaptic NMDAR were blocked by initially exposing hip-
pocampal cultures to the GABA antagonist bicuculline (50 M) and the
activity-dependent NMDAR antagonist MK801 (10 M). Subsequently,
cells were treated with NMDA (1 or 5 M; 15 min), washed and
exposed to DEX (1 M) for a further 72 h when apoptosis was
measured. Results (meansS.D. from four experiments, with four
replicates for each data point) show that blockade of synaptic NMDAR
prevents low doses of NMDA to counteract the apoptotic actions of
DEX. * and *** indicate significant differences where P0.05 and
0.001, respectively.
Fig. 5. Ifenprodil attenuates low dose NMDA-induced neuroprotec-
tion. Pharmacological blockade of the NR2B subunit of the NMDAR
was achieved by pre-incubating cells with ifenprodil (IFEN, 10 M).
Subsequently, the ability of low doses of NMDA (1 or 5 M) to protect
against the apoptotic effects of DEX (1 M; 72 h) was examined. The
data (meansS.D. derived from three experiments, with three repli-
cates for each data point) show that the protective effects of NMDA are
markedly attenuated when NR2B-containing NMDAR are rendered
non-functional by IFEN. * and ** indicate significant differences where
P0.05 and 0.01, respectively.
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form is Ca2-dependent, and is accompanied by cell
shrinkage, membrane blebbing and nuclear condensation
and fragmentation (karyoklasis); all of the latter features
are typical of apoptosis (Choi, 1991). In the present work,
the dominant form of cell death observed following treat-
ment of hippocampal cells with both NMDA and DEX was
of the apoptotic type.
The NMDAR has been the most intensely studied
GluR, especially in the context of neurotoxicity. NMDAR
are heteromeric in nature; they consist of a common
NMDA receptor subunit 1 and one or more NR2 subunits
(NR2A-D), whose insertion in the NMDAR complex varies
during development and maturity of synapses (Li et al.,
1998; Stocca and Vicini, 1998; Tovar and Westbrook,
1999). For example, it is known that whereas NR2A is
predominantly found in NMDAR located at the synapse,
NR2B are localized almost exclusively in NMDAR at ex-
trasynaptic (non-synaptic) sites. An important concept that
has emerged from recent studies is that synaptic NMDAR
can initiate neuroprotective mechanisms; in contrast, acti-
vation of extrasynaptic NMDAR results in cell death (Har-
dingham et al., 2002). The present experiments demon-
strate that selective inhibition of NR2B with ifenprodil re-
sults in a suppression of DEX-induced apoptosis (Fig. 2);
this finding is consistent with the documented efficacy of
ifenprodil in retarding cell death in various animal models
of neurodegenerative disease (for review see Chenard and
Menniti, 1999).
Previous work which showed that GluR stimulation can
result in excitotoxicity and that the latter can be amplified
by pre-treatment with glucocorticoids (Goodman et al.,
1996; Behl et al., 1997; Abraham et al., 2001; Johnson et
al., 2002) prompted us to examine the effects of NMDA
pre-treatment on DEX-induced apoptosis. To do this, we
treated hippocampal cultures with NMDA at doses ranging
from 1 to 10 M for a brief period (15 min) before exposure
to DEX (1 M) for 72 h. We observed a complete abolition
of the apoptotic actions of DEX when cells were pre-
exposed to NDMA at 1 and 5 M; at a dose of 10 M,
NMDA resulted in overt necrosis (Fig. 3). Subtoxic concen-
trations of NMDA are indeed known to elicit neurotrophic
and anti-apoptotic mechanisms in neurons (Marini et al.,
1998; Resink et al., 1996; Brandoli et al., 1998); moreover,
one of the implicated neurotrophins, brain-derived nerve
growth factor, has been found to stimulate (pro-survival)
NR2A subunit expression and to suppress NR2B (death-
promoting) expression (Glazner and Mattson, 2000). Be-
cause our experimental paradigm involved chronic expo-
sure to DEX, it is pertinent to mention a study which
showed that GR activation leads to an increase in NR2B
subunit gene expression with a concomitant decrease in
the expression of the gene encoding NR2A subunit (Nair et
al., 1998).
As noted above, NMDAR including the death-promot-
ing NR2B subunit are predominantly localized at extrasyn-
aptic sites; in contrast those comprising the pro-survival
NR2A subunit have a synaptic location (Riccio and Ginty,
2002). Since the appearance of NR2A- and NR2B-contain-
ing NMDAR is correlated with the ontogeny of synapses
(Tovar and Westbrook, 1999; Li et al., 1998; Stocca and
Vicini, 1998), it is pertinent to note that although the cul-
tures used for the present studies were relatively young
(experiments carried out after 6 days in vitro), cell–cell
interactions were abundantly evident at the light micro-
scopic level. In order to distinguish between synaptic and
extrasynaptic NMDAR in the mediation of the protective
actions of low doses of NMDA against DEX-stimulated
apoptosis, we adopted the recently described elegant
pharmacological paradigm described by Hardingham et al.
(2002). Briefly, the paradigm which consists of pre-treating
(15 min) hippocampal cultures with the GABA antagonist
bicuculline (to activate synaptic GluR) and MK801 (to block
active NMDAR) prevents NMDA activation of neuroprotec-
tive signaling cascades, leaving only extrasynaptic NR2B-
containing NMDAR available for NMDA binding. Cultures
pre-treated in this way were subsequently exposed to 1 or
5 M NMDA and DEX, after which they were analyzed for
apoptosis. The observation that the bicuculline/MK801
pre-treatment abrogated the ability of NMDA to oppose the
apoptotic actions of DEX (Fig. 4) is consistent with a syn-
aptic site of NMDA-induced neuroprotection (cf. Harding-
ham et al., 2002).
In an experiment to examine the impact of NR2B sub-
unit-containing NMDAR blockade on the neuroprotection
afforded by subtoxic NMDA doses against DEX-elicited
apoptosis, NR2B blockade was achieved by pre-treating
cells with NMDA and ifenprodil. It was reasoned that this
experimental design would ensure binding of ifenprodil, an
activity-dependent antagonist, to extrasynaptic receptors
and, at the same time, permit (or even enhance) the ac-
tivity of synaptic NMDAR. Contrary to expectations, we
observed that the NR2B-blocking procedure led to an am-
plification of DEX-induced apoptosis (Fig. 5). Only specu-
lative explanations can be offered for this finding at
present. Assuming similar affinities of NMDA for NR2A and
NR2B, and that neuroprotective NR2A are predominantly
occupied under basal conditions, a tenable explanation is
that, as extracellular glutamate concentrations increase,
neuronal fate is balanced by NR2A versus NR2B activity.
Also, since the NMDA/ifenprodil pre-treatment was tran-
sient (15 min), it could be that the prolonged exposure to
DEX resulted in increased sensitivity and/or up-regulation
of the synthesis of death-promoting NR2B receptors, or
equally, a down-regulation of pro-survival NR2A receptors;
the likelihood of such a mechanism is supported by the
observation that extended exposure to ifenprodil abro-
gated the neurotoxic actions of DEX (Fig. 2). In this con-
text, it should be noted that the GR is a potent transcrip-
tional factor. Thus, another plausible explanation would be
that by employing transcriptional mechanisms to elevate
glutamate synthesis (A´braha´m et al., 1996), DEX would
effectively make more neurotoxic glutamate available for
activating NR2 subunit NMDAR, thus positively driving a
vicious circle. Further studies are required to clarify these
issues.
A role for mGluR was demonstrated by the finding that
E4CPG and CPPG, selective antagonists of mGluR I/II and
II/III, respectively, can rescue hippocampal cells from
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DEX-induced apoptosis; strikingly, it was observed that
mGluR antagonism can also improve neuronal survival
under basal conditions (Fig. 2). In general, the manifesta-
tion of mGluR-mediated actions are slow and involve gene
activation. Type I mGluR have been associated with neu-
ronal death (Snyder et al., 2001; Allen et al., 2001; Miske-
vich et al., 2002; Heidinger et al., 2002) while Type II/III
mGluR have been shown to contribute to neuronal sur-
vival. The present results, using a cocktail of relatively
non-selective antagonists because of the unavailability of
more receptor type-specific drugs are interesting: they
suggest the involvement of either complex regulatory in-
teractions between the various mGluR or the up-regulation
of neurotoxic type I mGluR by DEX.
The present paper represents the first attempt to un-
derstand the mechanistic and functional nature of interac-
tions between GluR and glucocorticoids. Its results dem-
onstrate that the apoptotic actions of DEX are at least
partly mediated by GluR of the NMDA and metabotropic
types. In addition, the results reported herein show that low
doses of NMDA, acting via synaptic NMDAR can effec-
tively block hippocampal cell death induced by DEX. Last,
this work indicates that glucocorticoids can cause apopto-
sis in hippocampal cells by triggering rapid (NMDAR-me-
diated) as well as slow (mGluR- or GR-mediated) re-
sponses, and that the final outcome of glucocorticoid treat-
ment on hippocampal cell survival depends on the
convergence and integration of transcriptional signals (e.g.
GluR and agonist availability; regulation of apoptosis-re-
lated genes) and signals originating at the cell membrane
(e.g. Ca2 conductance). Although the present findings
are consistent with previous findings, it should be noted
that the present experiments were carried out on cells
obtained from neonatal hippocampal tissue; therefore, the
mechanisms described here do not necessarily apply to
the adult hippocampus which has been the focus of the
majority of in vivo studies of the neurotoxic actions of
glucocorticoids. A second caveat concerns the fact that the
serum-free medium used for the cell cultures favored the
survival of neurons rather than glia (neuronal–glial ratio
approximately 10:1 versus 1:10 in vivo). Since astrocytic
glutamate transporters are important for maintaining low
extracellular glutamate concentrations (Nedergaard et al.,
2002), the results obtained here more likely represent an
extreme situation rather the physiological norm. In this
context, it is also important to remember that the dose of
DEX (1 M) used in these in vitro experiments is high in
relation to the nanomolar concentrations of bioavailable
corticosterone that brain neurons are exposed to (Linthorst
et al., 2000). Therefore, caution is required in directly
extrapolating the present observations to the situation in
the organism.
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